---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-25-000052"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:53:13.846963+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00

## Summary
- Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).
- Gross margin 85.8% vs 84.1% YoY, driven by higher volume and Inspire V mix with lower COGS.
- Net income $9.9M ($0.34 diluted EPS) vs $18.5M ($0.60) prior year; adjusted diluted EPS $0.38.
- FY2025 revenue guidance reaffirmed $900M-$910M (12-13% growth); EPS guidance raised to $0.90-$1.00 from $0.40-$0.50.
- Completed $50M in share repurchases; Q3 operating cash flow $68.5M; cash & investments $410.9M.

## SEC filing metadata
- accession: 0001609550-25-000052
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000052/0001609550-25-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000052/insp-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-25-000052
- JSON: https://secwatch.observer/filing/0001609550-25-000052.json
- Plain text: https://secwatch.observer/filing/0001609550-25-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.